Bitter Melon for Diabetes: Dosage, Benefits and Evidence

Charantin, polypeptide-p and vicine are the named constituents. Polypeptide-p has been described as insulin-like, and proposed mechanisms include improved peripheral glucose uptake and AMPK activation. The gap between mechanistic plausibility and trial results is wide here.

• Fasting glucose and HbA1c: earlier meta-analyses found improvement on low to very low quality evidence; the 2024 analysis found no significant effect.
• Lipid profile: examined in a 2024 review alongside glycaemic indices, with similarly modest findings.
• Nutritional value: as a vegetable it is a reasonable food. As a supplement the case is unproven.

The fair reading is that the effect, if any, is smaller than early enthusiasm suggested.

A 2024 systematic review and meta-analysis of nine randomised trials in 414 patients concluded that the metabolic effect of Momordica charantia cannot be determined from the available clinical evidence. A 2024 review of glycaemic control and lipid profile in type 2 diabetes and a 2018 meta-analysis reach more favourable but still cautious conclusions on weaker evidence.

Trials use a wide range, roughly 500 mg to 2,000 mg/day of extract, or several grams of fruit powder, over 4-16 weeks. There is no consensus effective dose, which is itself a signal about the state of the evidence.

GI upset, abdominal pain and diarrhoea are common. It can cause hypoglycaemia, particularly alongside glucose-lowering medication. The seeds contain vicine and can trigger favism in people with G6PD deficiency.

Additive with insulin and oral glucose-lowering drugs, with a real hypoglycaemia risk requiring monitoring. Avoid in pregnancy: it has abortifacient activity in animal work. People with G6PD deficiency should avoid the seeds entirely.